View Future GrowthNabaltec 過去の業績過去 基準チェック /26Nabaltecは、平均年間14.7%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 減少しています。収益は、平均年間4.4% 2%収益成長率で 成長しています。 Nabaltecの自己資本利益率は5.4%であり、純利益率は4.4%です。主要情報14.65%収益成長率14.31%EPS成長率Chemicals 業界の成長12.41%収益成長率2.01%株主資本利益率5.42%ネット・マージン4.43%次回の業績アップデート20 Aug 2026最近の業績更新Reported Earnings • May 22First quarter 2026 earnings released: EPS: €0.20 (vs €0.31 in 1Q 2025)First quarter 2026 results: EPS: €0.20 (down from €0.31 in 1Q 2025). Revenue: €54.1m (down 1.8% from 1Q 2025). Net income: €1.80m (down 35% from 1Q 2025). Profit margin: 3.3% (down from 5.0% in 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 19% per year.お知らせ • Dec 11+ 3 more updatesNabaltec AG to Report Fiscal Year 2025 Results on Apr 30, 2026Nabaltec AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026お知らせ • Feb 16+ 3 more updatesNabaltec AG to Report Q3, 2025 Results on Nov 20, 2025Nabaltec AG announced that they will report Q3, 2025 results on Nov 20, 2025Reported Earnings • Aug 25Second quarter 2024 earnings released: EPS: €0.46 (vs €0.27 in 2Q 2023)Second quarter 2024 results: EPS: €0.46 (up from €0.27 in 2Q 2023). Revenue: €55.2m (up 12% from 2Q 2023). Net income: €4.07m (up 69% from 2Q 2023). Profit margin: 7.4% (up from 4.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • May 26First quarter 2024 earnings released: EPS: €0.39 (vs €0.35 in 1Q 2023)First quarter 2024 results: EPS: €0.39 (up from €0.35 in 1Q 2023). Revenue: €55.0m (down 3.8% from 1Q 2023). Net income: €3.40m (up 9.7% from 1Q 2023). Profit margin: 6.2% (up from 5.4% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: EPS: €1.30 (down from €3.00 in FY 2022). Revenue: €203.3m (down 7.4% from FY 2022). Net income: €11.4m (down 57% from FY 2022). Profit margin: 5.6% (down from 12% in FY 2022). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesReported Earnings • May 22First quarter 2026 earnings released: EPS: €0.20 (vs €0.31 in 1Q 2025)First quarter 2026 results: EPS: €0.20 (down from €0.31 in 1Q 2025). Revenue: €54.1m (down 1.8% from 1Q 2025). Net income: €1.80m (down 35% from 1Q 2025). Profit margin: 3.3% (down from 5.0% in 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 19% per year.Declared Dividend • May 20Dividend of €0.29 announcedDividend of €0.29 is the same as last year. Ex-date: 25th June 2026 Payment date: 29th June 2026 Dividend yield will be 2.7%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 9.2% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 12+ 1 more updateNabaltec AG announces Annual dividend, payable on June 29, 2026Nabaltec AG announced Annual dividend of EUR 0.2900 per share payable on June 29, 2026, ex-date on June 25, 2026 and record date on June 26, 2026.お知らせ • Dec 11+ 3 more updatesNabaltec AG to Report Fiscal Year 2025 Results on Apr 30, 2026Nabaltec AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026お知らせ • Jun 26Nabaltec AG Resolves to Distribute A DividendNabaltec AG at the AGM held on 25 June 2025, resolved to distribute a dividend totaling EUR 2.55 million, which corresponds to a payout of EUR 0.29 per share (previous year: EUR 0.28 per share). The remaining distributable profit of EUR 60.0 million will be carried forward to new account and thus contribute to strengthening the company’s equity – an important step in further implementing the company’s growth strategy.お知らせ • May 23Nabaltec Ag Affirms Earnings Guidance for 2025Nabaltec AG affirmed earnings guidance for 2025. For the period, the company expects Revenue growth in a range of 3% to 5%; EBIT margin in a range of 7% to 9%.お知らせ • May 13Nabaltec AG, Annual General Meeting, Jun 25, 2025Nabaltec AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.お知らせ • May 07Nabaltec AG announces Annual dividend, payable on June 30, 2025Nabaltec AG announced Annual dividend of EUR 0.2900 per share payable on June 30, 2025, ex-date on June 26, 2025 and record date on June 27, 2025.お知らせ • Feb 16+ 3 more updatesNabaltec AG to Report Q3, 2025 Results on Nov 20, 2025Nabaltec AG announced that they will report Q3, 2025 results on Nov 20, 2025New Risk • Aug 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.6% net profit margin).Reported Earnings • Aug 25Second quarter 2024 earnings released: EPS: €0.46 (vs €0.27 in 2Q 2023)Second quarter 2024 results: EPS: €0.46 (up from €0.27 in 2Q 2023). Revenue: €55.2m (up 12% from 2Q 2023). Net income: €4.07m (up 69% from 2Q 2023). Profit margin: 7.4% (up from 4.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Upcoming Dividend • Jun 19Upcoming dividend of €0.28 per shareEligible shareholders must have bought the stock before 26 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.2%).Reported Earnings • May 26First quarter 2024 earnings released: EPS: €0.39 (vs €0.35 in 1Q 2023)First quarter 2024 results: EPS: €0.39 (up from €0.35 in 1Q 2023). Revenue: €55.0m (down 3.8% from 1Q 2023). Net income: €3.40m (up 9.7% from 1Q 2023). Profit margin: 6.2% (up from 5.4% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Declared Dividend • May 13Dividend of €0.28 announcedShareholders will receive a dividend of €0.28. Ex-date: 26th June 2024 Payment date: 28th June 2024 Dividend yield will be 1.9%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (102% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Apr 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: EPS: €1.30 (down from €3.00 in FY 2022). Revenue: €203.3m (down 7.4% from FY 2022). Net income: €11.4m (down 57% from FY 2022). Profit margin: 5.6% (down from 12% in FY 2022). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jan 26Now 20% undervaluedOver the last 90 days, the stock has risen 18% to €17.10. The fair value is estimated to be €21.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €17.90, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 22% over the past three years.Buying Opportunity • Jan 10Now 20% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €21.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings is forecast to grow by 32% in the next 2 years.Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €18.65, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Chemicals industry in Germany. Total loss to shareholders of 30% over the past three years.Buying Opportunity • Nov 25Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €19.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings is forecast to grow by 32% in the next 2 years.Reported Earnings • Nov 23Third quarter 2023 earnings released: EPS: €0.33 (vs €1.38 in 3Q 2022)Third quarter 2023 results: EPS: €0.33 (down from €1.38 in 3Q 2022). Revenue: €51.1m (down 9.9% from 3Q 2022). Net income: €2.92m (down 76% from 3Q 2022). Profit margin: 5.7% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.New Risk • Nov 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.0% Last year net profit margin: 13% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.0% net profit margin).お知らせ • Nov 19+ 4 more updatesNabaltec AG to Report First Half, 2024 Results on Aug 22, 2024Nabaltec AG announced that they will report first half, 2024 results on Aug 22, 2024New Risk • Oct 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Buying Opportunity • Sep 08Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €21.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 82%. Revenue is forecast to grow by 7.8% in 2 years. Earnings is forecast to decline by 13% in the next 2 years.Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: €0.27 (vs €0.64 in 2Q 2022)Second quarter 2023 results: EPS: €0.27 (down from €0.64 in 2Q 2022). Revenue: €49.2m (down 12% from 2Q 2022). Net income: €2.41m (down 57% from 2Q 2022). Profit margin: 4.9% (down from 10.0% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.New Risk • Aug 18New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.2% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.お知らせ • Jun 29Nabaltec AG Approves DividendNabaltec AG announced that at its AGM held on June 28, 2023, the shareholders approved distribute a dividend totaling EUR 2.46 million. This corresponds to EUR 0.28 per share. The remaining distributable profit of EUR 41.1 million will be carried forward to new account and thus left in the company to further strengthen liquidity.Upcoming Dividend • Jun 22Upcoming dividend of €0.28 per share at 1.4% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 9.9% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (6.3%).お知らせ • May 26Nabaltec AG Provides Earnings Guidance for the Full Year 2023Nabaltec AG provided earnings guidance for the full year 2023. For the period, the company expects revenue growth of 3% to 5% and EBIT margin of 8% to 10%.Reported Earnings • May 03Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: €3.00 (up from €1.85 in FY 2021). Revenue: €222.8m (up 19% from FY 2021). Net income: €26.4m (up 62% from FY 2021). Profit margin: 12% (up from 8.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Revenue is expected to decline by 2.5% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.6%. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 28Price target decreased by 10% to €31.00Down from €34.50, the current price target is provided by 1 analyst. New target price is 35% above last closing price of €22.90. Stock is down 28% over the past year. The company is forecast to post earnings per share of €2.75 for next year compared to €1.85 last year.Price Target Changed • Nov 29Price target increased to €34.50Up from €31.50, the current price target is an average from 2 analysts. New target price is 45% above last closing price of €23.80. Stock is down 33% over the past year. The company is forecast to post earnings per share of €2.75 for next year compared to €1.85 last year.Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: €1.38 (vs €0.49 in 3Q 2021)Third quarter 2022 results: EPS: €1.38 (up from €0.49 in 3Q 2021). Revenue: €56.6m (up 21% from 3Q 2021). Net income: €12.1m (up 183% from 3Q 2021). Profit margin: 22% (up from 9.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years, in line with the revenue forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target decreased to €31.50Down from €36.00, the current price target is an average from 2 analysts. New target price is 53% above last closing price of €20.60. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.85 for next year compared to €1.85 last year.お知らせ • Nov 08+ 4 more updatesNabaltec AG, Annual General Meeting, Jun 28, 2023Nabaltec AG, Annual General Meeting, Jun 28, 2023.Price Target Changed • Oct 20Price target decreased to €31.50Down from €36.00, the current price target is an average from 2 analysts. New target price is 54% above last closing price of €20.50. Stock is down 36% over the past year. The company is forecast to post earnings per share of €2.03 for next year compared to €1.85 last year.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: €0.64 (vs €0.49 in 2Q 2021)Second quarter 2022 results: EPS: €0.64 (up from €0.49 in 2Q 2021). Revenue: €57.3m (up 19% from 2Q 2021). Net income: €5.60m (up 29% from 2Q 2021). Profit margin: 9.8% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 9.0%, compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 6% per year.Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to €26.90, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 8x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past three years.Upcoming Dividend • Jun 23Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 30 June 2022. Payment date: 04 July 2022. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.7%).Reported Earnings • Jun 04First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €0.53 (up from €0.27 in 1Q 2021). Revenue: €55.0m (up 19% from 1Q 2021). Net income: €4.67m (up 96% from 1Q 2021). Profit margin: 8.5% (up from 5.2% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%. Over the next year, revenue is forecast to grow 14%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Price Target Changed • May 24Price target decreased to €37.50Down from €41.00, the current price target is an average from 2 analysts. New target price is 37% above last closing price of €27.40. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.92 for next year compared to €1.85 last year.Reported Earnings • Apr 30Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: €1.85 loss per share (up from €2.23 loss in FY 2020). Revenue: €190.2m (up 19% from FY 2020). Net income: €16.3m (up €35.9m from FY 2020). Profit margin: 8.5% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 27Third quarter 2021 earnings: EPS exceeds analyst expectationsThird quarter 2021 results: EPS: €0.49 (up from €0.15 in 3Q 2020). Revenue: €47.4m (up 28% from 3Q 2020). Net income: €4.30m (up 217% from 3Q 2020). Profit margin: 9.1% (up from 3.6% in 3Q 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 4.4% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.Price Target Changed • Oct 29Price target increased to €40.50Up from €37.00, the current price target is an average from 3 analysts. New target price is 23% above last closing price of €33.00. Stock is up 66% over the past year. The company is forecast to post earnings per share of €1.50 next year compared to a net loss per share of €2.23 last year.Reported Earnings • Aug 27Second quarter 2021 earnings released: EPS €0.49 (vs €0.12 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €48.5m (up 33% from 2Q 2020). Net income: €4.35m (up €5.40m from 2Q 2020). Profit margin: 9.0% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance.Reported Earnings • May 28First quarter 2021 earnings released: EPS €0.27 (vs €0.14 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €46.1m (up 1.3% from 1Q 2020). Net income: €2.38m (up 98% from 1Q 2020). Profit margin: 5.2% (up from 2.6% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.Price Target Changed • May 15Price target increased to €37.00Up from €31.50, the current price target is an average from 2 analysts. New target price is 15% above last closing price of €32.20. Stock is up 56% over the past year.Reported Earnings • May 02Full year 2020 earnings released: €2.23 loss per share (vs €1.22 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €162.5m (down 9.6% from FY 2019). Net loss: €19.7m (down 284% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Price Target Changed • Apr 30Price target increased to €33.50Up from €30.50, the current price target is an average from 2 analysts. New target price is 6.0% above last closing price of €31.60. Stock is up 41% over the past year.Is New 90 Day High Low • Feb 27New 90-day high: €29.80The company is up 15% from its price of €25.90 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.95 per share.Is New 90 Day High Low • Nov 11New 90-day high: €23.00The company is up 21% from its price of €19.00 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €62.62 per share.Is New 90 Day High Low • Oct 11New 90-day high: €21.00The company is up 2.0% from its price of €20.60 on 13 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.09 per share.収支内訳Nabaltec の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:NTG 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Mar 26197943031 Dec 251991043030 Sep 252021243030 Jun 252031342031 Mar 252061442031 Dec 242051442030 Sep 242041441030 Jun 242041340031 Mar 241981240031 Dec 232011139030 Sep 232081241030 Jun 232152241031 Mar 232222541031 Dec 222202641030 Sep 222142839030 Jun 222052038031 Mar 221971937031 Dec 211881636030 Sep 21182-1035030 Jun 21172-1333031 Mar 21161-1832031 Dec 20160-2033030 Sep 20157234030 Jun 20164336031 Mar 20177837031 Dec 191801137030 Sep 191841337030 Jun 191831336031 Mar 191811135031 Dec 181771034030 Sep 181741034030 Jun 181721033031 Mar 181711233031 Dec 171691132030 Sep 17168934030 Jun 17165734031 Mar 17163633031 Dec 16160533030 Sep 16159729030 Jun 16158728031 Mar 16155628031 Dec 15152728030 Sep 15150628030 Jun 151497270質の高い収益: NTGは 高品質の収益 を持っています。利益率の向上: NTGの現在の純利益率 (4.4%)は、昨年(6.6%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NTG過去 5 年間で収益を上げており、収益は年間14.7%増加しています。成長の加速: NTGは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: NTGは過去 1 年間で収益成長率がマイナス ( -36% ) となったため、 Chemicals業界平均 ( -13.5% ) と比較することが困難です。株主資本利益率高いROE: NTGの 自己資本利益率 ( 5.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 10:54終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nabaltec AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Volker BosseBaader Helvea Equity ResearchAndrew KeenEdison Investment ResearchChristian SandherrHauck Aufhäuser Investment Banking1 その他のアナリストを表示
Reported Earnings • May 22First quarter 2026 earnings released: EPS: €0.20 (vs €0.31 in 1Q 2025)First quarter 2026 results: EPS: €0.20 (down from €0.31 in 1Q 2025). Revenue: €54.1m (down 1.8% from 1Q 2025). Net income: €1.80m (down 35% from 1Q 2025). Profit margin: 3.3% (down from 5.0% in 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 19% per year.
お知らせ • Dec 11+ 3 more updatesNabaltec AG to Report Fiscal Year 2025 Results on Apr 30, 2026Nabaltec AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026
お知らせ • Feb 16+ 3 more updatesNabaltec AG to Report Q3, 2025 Results on Nov 20, 2025Nabaltec AG announced that they will report Q3, 2025 results on Nov 20, 2025
Reported Earnings • Aug 25Second quarter 2024 earnings released: EPS: €0.46 (vs €0.27 in 2Q 2023)Second quarter 2024 results: EPS: €0.46 (up from €0.27 in 2Q 2023). Revenue: €55.2m (up 12% from 2Q 2023). Net income: €4.07m (up 69% from 2Q 2023). Profit margin: 7.4% (up from 4.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • May 26First quarter 2024 earnings released: EPS: €0.39 (vs €0.35 in 1Q 2023)First quarter 2024 results: EPS: €0.39 (up from €0.35 in 1Q 2023). Revenue: €55.0m (down 3.8% from 1Q 2023). Net income: €3.40m (up 9.7% from 1Q 2023). Profit margin: 6.2% (up from 5.4% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: EPS: €1.30 (down from €3.00 in FY 2022). Revenue: €203.3m (down 7.4% from FY 2022). Net income: €11.4m (down 57% from FY 2022). Profit margin: 5.6% (down from 12% in FY 2022). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • May 22First quarter 2026 earnings released: EPS: €0.20 (vs €0.31 in 1Q 2025)First quarter 2026 results: EPS: €0.20 (down from €0.31 in 1Q 2025). Revenue: €54.1m (down 1.8% from 1Q 2025). Net income: €1.80m (down 35% from 1Q 2025). Profit margin: 3.3% (down from 5.0% in 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 19% per year.
Declared Dividend • May 20Dividend of €0.29 announcedDividend of €0.29 is the same as last year. Ex-date: 25th June 2026 Payment date: 29th June 2026 Dividend yield will be 2.7%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 9.2% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 12+ 1 more updateNabaltec AG announces Annual dividend, payable on June 29, 2026Nabaltec AG announced Annual dividend of EUR 0.2900 per share payable on June 29, 2026, ex-date on June 25, 2026 and record date on June 26, 2026.
お知らせ • Dec 11+ 3 more updatesNabaltec AG to Report Fiscal Year 2025 Results on Apr 30, 2026Nabaltec AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026
お知らせ • Jun 26Nabaltec AG Resolves to Distribute A DividendNabaltec AG at the AGM held on 25 June 2025, resolved to distribute a dividend totaling EUR 2.55 million, which corresponds to a payout of EUR 0.29 per share (previous year: EUR 0.28 per share). The remaining distributable profit of EUR 60.0 million will be carried forward to new account and thus contribute to strengthening the company’s equity – an important step in further implementing the company’s growth strategy.
お知らせ • May 23Nabaltec Ag Affirms Earnings Guidance for 2025Nabaltec AG affirmed earnings guidance for 2025. For the period, the company expects Revenue growth in a range of 3% to 5%; EBIT margin in a range of 7% to 9%.
お知らせ • May 13Nabaltec AG, Annual General Meeting, Jun 25, 2025Nabaltec AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.
お知らせ • May 07Nabaltec AG announces Annual dividend, payable on June 30, 2025Nabaltec AG announced Annual dividend of EUR 0.2900 per share payable on June 30, 2025, ex-date on June 26, 2025 and record date on June 27, 2025.
お知らせ • Feb 16+ 3 more updatesNabaltec AG to Report Q3, 2025 Results on Nov 20, 2025Nabaltec AG announced that they will report Q3, 2025 results on Nov 20, 2025
New Risk • Aug 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.6% net profit margin).
Reported Earnings • Aug 25Second quarter 2024 earnings released: EPS: €0.46 (vs €0.27 in 2Q 2023)Second quarter 2024 results: EPS: €0.46 (up from €0.27 in 2Q 2023). Revenue: €55.2m (up 12% from 2Q 2023). Net income: €4.07m (up 69% from 2Q 2023). Profit margin: 7.4% (up from 4.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Jun 19Upcoming dividend of €0.28 per shareEligible shareholders must have bought the stock before 26 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.2%).
Reported Earnings • May 26First quarter 2024 earnings released: EPS: €0.39 (vs €0.35 in 1Q 2023)First quarter 2024 results: EPS: €0.39 (up from €0.35 in 1Q 2023). Revenue: €55.0m (down 3.8% from 1Q 2023). Net income: €3.40m (up 9.7% from 1Q 2023). Profit margin: 6.2% (up from 5.4% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Declared Dividend • May 13Dividend of €0.28 announcedShareholders will receive a dividend of €0.28. Ex-date: 26th June 2024 Payment date: 28th June 2024 Dividend yield will be 1.9%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (102% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Apr 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: EPS: €1.30 (down from €3.00 in FY 2022). Revenue: €203.3m (down 7.4% from FY 2022). Net income: €11.4m (down 57% from FY 2022). Profit margin: 5.6% (down from 12% in FY 2022). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jan 26Now 20% undervaluedOver the last 90 days, the stock has risen 18% to €17.10. The fair value is estimated to be €21.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €17.90, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 22% over the past three years.
Buying Opportunity • Jan 10Now 20% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €21.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings is forecast to grow by 32% in the next 2 years.
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €18.65, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Chemicals industry in Germany. Total loss to shareholders of 30% over the past three years.
Buying Opportunity • Nov 25Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €19.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings is forecast to grow by 32% in the next 2 years.
Reported Earnings • Nov 23Third quarter 2023 earnings released: EPS: €0.33 (vs €1.38 in 3Q 2022)Third quarter 2023 results: EPS: €0.33 (down from €1.38 in 3Q 2022). Revenue: €51.1m (down 9.9% from 3Q 2022). Net income: €2.92m (down 76% from 3Q 2022). Profit margin: 5.7% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
New Risk • Nov 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.0% Last year net profit margin: 13% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.0% net profit margin).
お知らせ • Nov 19+ 4 more updatesNabaltec AG to Report First Half, 2024 Results on Aug 22, 2024Nabaltec AG announced that they will report first half, 2024 results on Aug 22, 2024
New Risk • Oct 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Buying Opportunity • Sep 08Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €21.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 82%. Revenue is forecast to grow by 7.8% in 2 years. Earnings is forecast to decline by 13% in the next 2 years.
Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: €0.27 (vs €0.64 in 2Q 2022)Second quarter 2023 results: EPS: €0.27 (down from €0.64 in 2Q 2022). Revenue: €49.2m (down 12% from 2Q 2022). Net income: €2.41m (down 57% from 2Q 2022). Profit margin: 4.9% (down from 10.0% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
New Risk • Aug 18New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.2% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
お知らせ • Jun 29Nabaltec AG Approves DividendNabaltec AG announced that at its AGM held on June 28, 2023, the shareholders approved distribute a dividend totaling EUR 2.46 million. This corresponds to EUR 0.28 per share. The remaining distributable profit of EUR 41.1 million will be carried forward to new account and thus left in the company to further strengthen liquidity.
Upcoming Dividend • Jun 22Upcoming dividend of €0.28 per share at 1.4% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 9.9% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (6.3%).
お知らせ • May 26Nabaltec AG Provides Earnings Guidance for the Full Year 2023Nabaltec AG provided earnings guidance for the full year 2023. For the period, the company expects revenue growth of 3% to 5% and EBIT margin of 8% to 10%.
Reported Earnings • May 03Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: €3.00 (up from €1.85 in FY 2021). Revenue: €222.8m (up 19% from FY 2021). Net income: €26.4m (up 62% from FY 2021). Profit margin: 12% (up from 8.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Revenue is expected to decline by 2.5% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.6%. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 28Price target decreased by 10% to €31.00Down from €34.50, the current price target is provided by 1 analyst. New target price is 35% above last closing price of €22.90. Stock is down 28% over the past year. The company is forecast to post earnings per share of €2.75 for next year compared to €1.85 last year.
Price Target Changed • Nov 29Price target increased to €34.50Up from €31.50, the current price target is an average from 2 analysts. New target price is 45% above last closing price of €23.80. Stock is down 33% over the past year. The company is forecast to post earnings per share of €2.75 for next year compared to €1.85 last year.
Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: €1.38 (vs €0.49 in 3Q 2021)Third quarter 2022 results: EPS: €1.38 (up from €0.49 in 3Q 2021). Revenue: €56.6m (up 21% from 3Q 2021). Net income: €12.1m (up 183% from 3Q 2021). Profit margin: 22% (up from 9.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years, in line with the revenue forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target decreased to €31.50Down from €36.00, the current price target is an average from 2 analysts. New target price is 53% above last closing price of €20.60. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.85 for next year compared to €1.85 last year.
お知らせ • Nov 08+ 4 more updatesNabaltec AG, Annual General Meeting, Jun 28, 2023Nabaltec AG, Annual General Meeting, Jun 28, 2023.
Price Target Changed • Oct 20Price target decreased to €31.50Down from €36.00, the current price target is an average from 2 analysts. New target price is 54% above last closing price of €20.50. Stock is down 36% over the past year. The company is forecast to post earnings per share of €2.03 for next year compared to €1.85 last year.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: €0.64 (vs €0.49 in 2Q 2021)Second quarter 2022 results: EPS: €0.64 (up from €0.49 in 2Q 2021). Revenue: €57.3m (up 19% from 2Q 2021). Net income: €5.60m (up 29% from 2Q 2021). Profit margin: 9.8% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 9.0%, compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 6% per year.
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to €26.90, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 8x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past three years.
Upcoming Dividend • Jun 23Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 30 June 2022. Payment date: 04 July 2022. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.7%).
Reported Earnings • Jun 04First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €0.53 (up from €0.27 in 1Q 2021). Revenue: €55.0m (up 19% from 1Q 2021). Net income: €4.67m (up 96% from 1Q 2021). Profit margin: 8.5% (up from 5.2% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%. Over the next year, revenue is forecast to grow 14%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Price Target Changed • May 24Price target decreased to €37.50Down from €41.00, the current price target is an average from 2 analysts. New target price is 37% above last closing price of €27.40. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.92 for next year compared to €1.85 last year.
Reported Earnings • Apr 30Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: €1.85 loss per share (up from €2.23 loss in FY 2020). Revenue: €190.2m (up 19% from FY 2020). Net income: €16.3m (up €35.9m from FY 2020). Profit margin: 8.5% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 27Third quarter 2021 earnings: EPS exceeds analyst expectationsThird quarter 2021 results: EPS: €0.49 (up from €0.15 in 3Q 2020). Revenue: €47.4m (up 28% from 3Q 2020). Net income: €4.30m (up 217% from 3Q 2020). Profit margin: 9.1% (up from 3.6% in 3Q 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 4.4% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.
Price Target Changed • Oct 29Price target increased to €40.50Up from €37.00, the current price target is an average from 3 analysts. New target price is 23% above last closing price of €33.00. Stock is up 66% over the past year. The company is forecast to post earnings per share of €1.50 next year compared to a net loss per share of €2.23 last year.
Reported Earnings • Aug 27Second quarter 2021 earnings released: EPS €0.49 (vs €0.12 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €48.5m (up 33% from 2Q 2020). Net income: €4.35m (up €5.40m from 2Q 2020). Profit margin: 9.0% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 28First quarter 2021 earnings released: EPS €0.27 (vs €0.14 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €46.1m (up 1.3% from 1Q 2020). Net income: €2.38m (up 98% from 1Q 2020). Profit margin: 5.2% (up from 2.6% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.
Price Target Changed • May 15Price target increased to €37.00Up from €31.50, the current price target is an average from 2 analysts. New target price is 15% above last closing price of €32.20. Stock is up 56% over the past year.
Reported Earnings • May 02Full year 2020 earnings released: €2.23 loss per share (vs €1.22 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €162.5m (down 9.6% from FY 2019). Net loss: €19.7m (down 284% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Price Target Changed • Apr 30Price target increased to €33.50Up from €30.50, the current price target is an average from 2 analysts. New target price is 6.0% above last closing price of €31.60. Stock is up 41% over the past year.
Is New 90 Day High Low • Feb 27New 90-day high: €29.80The company is up 15% from its price of €25.90 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.95 per share.
Is New 90 Day High Low • Nov 11New 90-day high: €23.00The company is up 21% from its price of €19.00 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €62.62 per share.
Is New 90 Day High Low • Oct 11New 90-day high: €21.00The company is up 2.0% from its price of €20.60 on 13 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.09 per share.